IRTC — iRhythm Technologies, Inc.

iRhythm Holdings (IRTC) Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $199.4 million, up 25.7% year-over-year.
• Adjusted EBITDA: $14.1 million (7.1% of revenue), an improvement of 880 basis points year-over-year.
• Gross Margin: 70.9%, an increase of 210 basis points year-over-year.
• Net Loss: GAAP net loss of $13.9 million ($0.43 per diluted share), improved from a loss of $30.7 million in Q1 2025.
• Free Cash Flow: Negative $33 million, consistent with seasonal trends.
• Cash Position: $549.6 million in cash and equivalents, providing flexibility for growth initiatives.

2. Strategic Updates and Business Highlights

• Market Growth: Revenue growth driven by strong demand across Zio Monitor and Zio AT, with significant contributions from cardiology, primary care, innovative channels, and international markets.
• Long-Term Monitoring Strategy: iRhythm aims to redefine arrhythmia diagnosis by promoting longer-duration monitoring, addressing the limitations of short-duration monitors.
• Primary Care Expansion: Continued engagement in primary care settings, with approximately 53% of volume flowing through EHR-integrated accounts.
• AI Integration: Development of a next-generation AI algorithm expected to halve clinical technician review time, enhancing operational efficiency.
• Regulatory Progress: Ongoing efforts to address FDA concerns from a warning letter, with a comprehensive review of the quality management system completed without material observations.
• International Opportunities: Strong performance in the U.K. and updates in Japan's reimbursement framework, signaling potential for future growth.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Raised to $875 million - $885 million, reflecting 17% to 18% year-over-year growth.
• Q2 2026 Revenue Expectation: Anticipated between $218 million and $220 million.
• Adjusted EBITDA Margin Guidance: Increased to 12% - 13% for the full year.
• Free Cash Flow: Expected to grow in 2026 compared to 2025, with seasonality affecting the timing.

4. Challenges and Points of Concern

• Regulatory Scrutiny: Ongoing FDA warning letter and a DOJ investigation related to the AT product line, with no new requests for information but uncertainty remains.
• Market Competition: Concerns about potential competition from AI-driven entrants in the medtech space, although management believes in their defensibility due to their comprehensive service offering.
• Geopolitical Risks: Current geopolitical situation could impact margins, but management has implemented cost containment measures.

5. Notable Q&A Insights

• Guidance Adjustments: Management indicated that the raised guidance reflects a cautious approach, considering potential challenges in the latter half of the year due to tougher year-over-year comparisons.
• AI Competition: Management expressed confidence in their market position, emphasizing the integration of AI within a broader service model rather than just software capabilities.
• Sleep Market Potential: Management is optimistic about the sleep diagnostics market but does not expect significant contributions until 2027.
• Electrophysiology (EP) Market: No current signs of slowdown in EP procedures, but management is aware of the importance of longer-duration monitoring post-ablation.
• International Reimbursement: While Japan's reimbursement framework has improved slightly, management is focused on further enhancing reimbursement rates through ongoing clinical studies.

This summary encapsulates the key aspects of iRhythm's Q1 2026 earnings call, highlighting both the company's strong performance and the challenges it faces moving forward.